Oncofusion Enters Into License Agreement with Medivation for Compounds Targeting Bromodomain Proteins

San Francisco, CA and Ann Arbor, MI –  April 23, 2014 – Medivation, Inc. (Nasdaq: MDVN) and OncoFusion Therapeutics, Inc., today announced that they have entered into a research and  license agreement for certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins for potential use in oncology and other disease areas.  Medivation will gain exclusive worldwide… Read More